Data presented at ASH 2021 congress show 83 percent of patients achieved a stringent complete response at median follow-up of 22 months1 92 percent of evaluable patients achieved minimal residual
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with.
Submission based on data from pivotal CARTITUDE-1 trialSOMERSET, N.J. (BUSINESS WIRE) $LEGN Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Ministr.
After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the